Center for the Development of Therapeutics

Identification of small molecule inhibitors of PPM1D using an integrated drug discovery platform.

Shaw S, Jiang W, Rush J, et al. Identification of small molecule inhibitors of PPM1D using an integrated drug discovery platform. iScience. 2025;28(3):112069. doi:10.1016/j.isci.2025.112069PubMed Google Scholar DOI

Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes.

Ewald JD, Titterton KL, Bäuerle A, et al. Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes. bioRxiv : the preprint server for biology. 2025. doi:10.1101/2025.01.22.634152PubMed Google Scholar DOI

A non-hormonal reversible contraceptive targeting GSK3α, a protein kinase, essential for epididymal sperm maturation.

Kabi M, Khamamkar A, Kyei-Baffour K, Weïwer M, Vijayaraghavan S, Dey S. A non-hormonal reversible contraceptive targeting GSK3α, a protein kinase, essential for epididymal sperm maturation. Andrology. 2025. doi:10.1111/andr.13838PubMed Google Scholar DOI

Disrupted uromodulin trafficking is rescued by targeting TMED cargo receptors.

Bazua-Valenti S, Brown MR, Zavras J, et al. Disrupted uromodulin trafficking is rescued by targeting TMED cargo receptors. The Journal of clinical investigation. 2024;134(24). doi:10.1172/JCI180347PubMed Google Scholar DOI

Three million images and morphological profiles of cells treated with matched chemical and genetic perturbations.

Chandrasekaran SN, Cimini BA, Goodale A, et al. Three million images and morphological profiles of cells treated with matched chemical and genetic perturbations. Nature methods. 2024. doi:10.1038/s41592-024-02241-6PubMed Google Scholar DOI

The benefits of translating biomedical research at drug discovery institutes.

Huggins DJ, Baell J, Brennan PE, Burgin A, Scott DE. The benefits of translating biomedical research at drug discovery institutes. Nature reviews. Drug discovery. 2024. doi:10.1038/d41573-024-00142-zPubMed Google Scholar DOI

BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.

Rauh U, Wei G, Serrano-Wu M, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature cancer. 2024. doi:10.1038/s43018-024-00814-0PubMed Google Scholar DOI

Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint.

Tsao HW, Anderson S, Finn KJ, et al. Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. Immunity. 2024. doi:10.1016/j.immuni.2024.10.013PubMed Google Scholar DOI

Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors.

Pecci F, Nakazawa S, Ricciuti B, et al. Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors. Cancer discovery. 2024. doi:10.1158/2159-8290.CD-23-1217PubMed Google Scholar DOI

Mapping MAVE data for use in human genomics applications.

Arbesfeld JA, Da EY, Stevenson JS, et al. Mapping MAVE data for use in human genomics applications. bioRxiv : the preprint server for biology. 2024. doi:10.1101/2023.06.20.545702PubMed Google Scholar DOI